References
- Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet [Internet]. 2014;384(9939):241–248. http://www.ncbi.nlm.nih.gov/pubmed/2504223410.1016/S0140-6736(14)60604-8
- Bower M, Collins S, Cottrill C, et al. British HIV association guidelines for HIV-associated malignancies 2008. HIV Med [Internet]. 2008;9(6):336–388. http://www.ncbi.nlm.nih.gov/pubmed/1870575910.1111/hiv.2008.9.issue-6
- Bower M, Stebbing J, Tuthill M, et al. Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma. Blood [Internet]. 2008;111(8):3986–3990. http://www.ncbi.nlm.nih.gov/pubmed/1817200410.1182/blood-2007-10-115659
- Spagnuolo V, Galli L, Salpietro S, et al. Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies. Int J Cancer [Internet]. 2012;130(12):2990–2996. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2179663310.1002/ijc.26332
- Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol [Internet]. 2012;30(33):4111–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23045581
- Minuesa G, Huber-Ruano I, Pastor-Anglada M, Koepsell H, Clotet B, Martinez-Picado J. Drug uptake transporters in antiretroviral therapy. Pharmacol Ther. 2011;132(3):268–279.10.1016/j.pharmthera.2011.06.007
- Nigam SK. What do drug transporters really do? Nat Rev Drug Discov [Internet]. 2015 Jan;14(1):29–44. Available from: http://dx.doi.org/10.1038/nrd4461
- Persidis A. Cancer multidrug resistance. Nat Biotech.. 1999 Jan;17(1):94–5. PMID: 9920278. doi: 10.1038/5289
- Yuen AR, Sikic BI. Multidrug resistance in lymphomas. J Clin Oncol. 1994 Nov;12(11):2453–9.
- Tulpule A. Multidrug resistance in AIDS-related lymphoma. Curr Opin Oncol [Internet]. 2005;17(5):466–468. http://www.ncbi.nlm.nih.gov/pubmed/1609379710.1097/01.cco.0000172825.85942.d6
- Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311–8.
- Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997;40Suppl: S13–S19.10.1007/s002800051055
- Zembruski NC, Buchel G, Jodicke L, Herzog M, Haefeli WE, Weiss J. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J Antimicrob Chemother [Internet]. 2011;66(4):802–812. http://www.ncbi.nlm.nih.gov/pubmed/2139317410.1093/jac/dkq501
- Noguchi K, Katayama K, Sugimoto Y. Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers Med [Internet]. 2014;7:53–64. http://www.ncbi.nlm.nih.gov/pubmed/24523596
- Giraud C, Manceau S, Treluyer JM. ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies. Expert Opin Drug Metab Toxicol [Internet]. 2010;6(5):571–589. http://www.ncbi.nlm.nih.gov/pubmed/2036710910.1517/17425251003601953
- Simonelli C, Zanussi S, Cinelli R, et al. Virological efficacy in HIV-infected patients affected by non-hodgkin lymphoma, treated with antiblastic chemotherapy and highly active antiretroviral therapy. Scand J Infect Dis Suppl. 2003;35:49–53.10.1080/03008870310009678
- O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015 Nov;60(4):547–560.10.1016/j.molcel.2015.10.040
- Kis O, Robillard K, Chan GN, Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci [Internet]. 2010;31(1):22–35. http://www.ncbi.nlm.nih.gov/pubmed/2000448510.1016/j.tips.2009.10.001
- Owen A, Chandler B, Back DJ. The implications of P-glycoprotein in HIV: friend or foe? Fundam Clin Pharmacol. 2005 Jun;19(3):283–296.10.1111/fcp.2005.19.issue-3
- Janneh O, Hartkoorn RC, Jones E, et al. Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. British J Pharmacol. 2008;155:875–883.10.1038/bjp.2008.320
- Chandler B, Detsika M, Khoo SH, Williams J, Back DJ, Owen A. Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. J Antimicrob Chemother. 2007 Sep;60(3):685–689.10.1093/jac/dkm230
- No Title. Stanford University Drug Resistance database. http://hivdb.stanford.edu/DR/NRTIResiNote.html. Accessed November 13, 2014.
- McColl DJ, Margot N, Chen S-S, Harris J, Borroto-Esoda K, Miller MD. Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz. HIV Clin Trials. 2011;12(2):61–70.10.1310/hct1202-61
- Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst [Internet]. 1993;85(8):632–639. http://www.ncbi.nlm.nih.gov/pubmed/809687510.1093/jnci/85.8.632
- Simonelli C, Zanussi S, Cinelli R, et al. Impact of Concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV‐infected patients with non‐hodgkin lymphoma. Clin Infect Dis [Internet]. 2003;37(6):820–827. http://www.ncbi.nlm.nih.gov/pubmed/1295564410.1086/cid.2003.37.issue-6